Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.36 |
| ▸ | GSK3A | P49840 | 3/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | OTUD7B | Q6GQQ9 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14867079 | 0.80 | BRD4 (0.44) | GSK3BGSK3APDE3BPDE3ACDK5 | |
| SCHEMBL19069631 | 0.77 | GRM5 (0.43) | GSK3BGSK3APDE3BPDE3ACDK5 | |
| SCHEMBL12230597 | 0.77 | CRBN (0.38) | GSK3BGSK3ACRBNOTUD7B | |
| SCHEMBL828845 | 0.75 | BRD4 (0.49) | BRD4RIPK1 | |
| SCHEMBL14279926 | 0.74 | KCNQ2 (0.36) | TSHR | |
| SCHEMBL2233893 | 0.71 | NPC1 (0.50) | GSK3BGSK3APDE3BPDE3ACDK5 | |
| SCHEMBL30493623 | 0.71 | NPC1 (0.50) | GSK3BGSK3APDE3BPDE3ACDK5 | |
| SCHEMBL17881393 | 0.70 | BRD4 (0.54) | GSK3BGSK3APDE3BPDE3ACDK5 | |
| SCHEMBL13999790 | 0.70 | MAPK1 (0.39) | BRD4CYP3A4TSHRNFKB1THPO | |
| Hydrochloric Acid SCHEMBL5107756 | 0.69 | MAPK1 (0.38) | CYP3A4TSHRNFKB1THPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-01 | — | — | US | disclosed |
| US-9695176-B2 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695176-B2 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150274734-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-01 | — | — | US | disclosed |
| US-8748429-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130096130-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130053570-A1 | CGRP Receptor Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-02-28 | — | — | US | disclosed |
| US-8314117-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | GSK3B 1058/4885GSK3A 1465/4885PDE3B 197/4885 |
| US-20180030057-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, BDKRB2 | GSK3B 2693/4885GSK3A 3038/4885PDE3B 257/4885 |
| US-20130053570-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | GSK3B 1176/4885GSK3A 1527/4885PDE3B 184/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | GSK3B 1058/4885GSK3A 1465/4885PDE3B 197/4885 |
| US-20130096130-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | GSK3B 1176/4885GSK3A 1527/4885PDE3B 184/4885 |
| US-20150274734-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, BDKRB2, CALCR | GSK3B 1326/4885GSK3A 1812/4885PDE3B 266/4885 |
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | GSK3B 1176/4885GSK3A 1527/4885PDE3B 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.